Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2024-09-27 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
Regulatory Filings Classification · 95% confidence The document is explicitly titled and formatted as a 'Press Release' dated September 27, 2024. It announces a specific business development: Photocure establishing a Named Patient Program (NPP) in South Africa for its drug Hexvix. This type of announcement, detailing operational news, partnerships, or specific market access updates outside of mandatory financial reporting (like 10-K, ER, or IR), typically falls under general regulatory announcements or news releases. Since there is no specific category for 'Press Release' and it is not a financial report, an earnings release, or a management discussion, the most appropriate classification is the general regulatory/news fallback category, RNS (Regulatory Filings). The document length (6319 chars) is substantial enough that it is the primary content, not just an announcement of another document.
2024-09-27 English
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as a 'Press Release' announcing a business development: Photocure establishing a Named Patient Program (NPP) in South Africa for Hexvix. This type of announcement, detailing strategic agreements, product access initiatives, and general corporate news, is characteristic of a general corporate announcement rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a press release announcing corporate activity that doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory/corporate announcements not covered elsewhere. Given the content is a standard press release, RNS is the best fit among the provided options.
2024-09-27 English
Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference
Regulatory Filings Classification · 99% confidence The document is explicitly titled "Press Release" and announces that Photocure's partner, Asieris, has unveiled efficacy data for Cevira at a conference. It details clinical trial results (Phase III data, regression rates, p-values) but is presented as an announcement of data presentation rather than the full, comprehensive financial report (like 10-K or IR). Since it is a press release announcing clinical/scientific progress and data, it does not fit the specific categories like ER (Earnings Release), AR (Audit Report), or IR (Interim Report). It is a general corporate announcement regarding product development milestones. Given the options, the most appropriate classification for a general corporate announcement that isn't a specific financial filing, management change, or dividend notice is the general Regulatory Filings category (RNS), as it is a public disclosure of material information, although it could also be argued as an Investor Presentation (IP) if it were the slides themselves. However, as a press release detailing trial results, RNS serves as the best fit among the provided codes for non-standard, material corporate news.
2024-09-17 English
Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference
Regulatory Filings Classification · 100% confidence The document is explicitly titled as a 'Press Release' announcing that Photocure's partner, Asieris, unveiled efficacy data for the Cevira product at a conference. It details clinical trial results (Phase III data, regression rates, p-values) and provides links to the partner's full media release. This content is a direct announcement of scientific/clinical progress, not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a formal dividend notice. It is best classified as an Earnings Release (ER) if it were tied to financial results, but since it is purely clinical/pipeline news, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially an Investor Presentation (IP) if it were a slide deck, but as a press release detailing data, RNS is the most appropriate general category for non-standard announcements, or ER if we interpret clinical updates as part of periodic reporting context, though RNS is safer for pure pipeline news. Given the options, and that it is a press release announcing data, RNS (Regulatory Filings/General Announcement) is the most suitable fallback for non-standard corporate news that isn't a specific financial report or management change.
2024-09-17 English
Notification of major shareholding
Major Shareholding Notification Classification · 98% confidence The document is titled "Standard form for notification of major holdings" and explicitly deals with the acquisition or disposal of voting rights, referencing specific articles of Directive 2004/109/EC (a European transparency directive). Section 6 and 7 detail the resulting percentage of voting rights and the total number of shares. This structure is characteristic of a notification required when an investor's stake crosses a major holding threshold. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the most appropriate classification for reporting changes in significant share ownership levels that cross defined thresholds.
2024-09-16 English
Notification of major shareholding
Major Shareholding Notification Classification · 98% confidence The document text explicitly states "Notification of major shareholding" and directs the user to an attachment on an external news service (www.newsweb.no). This indicates a formal announcement regarding a change in significant ownership, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Given the extremely short length (108 characters) and the instruction to 'See attachment', it is an announcement of the filing rather than the full filing itself, but MRQ is the most specific category for the content described.
2024-09-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.